about
Malaria Prevention in Short-Term TravelersZika virus and microcephaly: why is this situation a PHEIC?Medical Considerations before International TravelInternational travelers as sentinels for sustained influenza transmission during the 2009 influenza A(H1N1)pdm09 pandemic.Health risks in travelers to South Africa: the GeoSentinel experience and implications for the 2010 FIFA World Cup.Internet and computer-based resources for travel medicine practitioners.Expatriates ill after travel: results from the Geosentinel Surveillance NetworkGeoSentinel surveillance of illness in returned travelers, 2007-2011Immune dynamics in the pathogenesis of human lymphatic filariasis.Acute and potentially life-threatening tropical diseases in western travelers--a GeoSentinel multicenter study, 1996-2011Etiology of travel-related fever.Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997-2006.Travel-associated illness trends and clusters, 2000-2010.A comparative analysis of methodological approaches used for estimating risk in travel medicine.Expert opinion on vaccination of travelers against Japanese encephalitis.Global health surveillance and travelers' health.Surveillance report of Zika virus among Canadian travellers returning from the Americas.Spectrum of disease and relation to place of exposure among ill returned travelers.Gastrointestinal infection among international travelers globally.The practice of travel medicine: guidelines by the Infectious Diseases Society of America.Sex and gender differences in travel-associated disease.Should health-care providers in the United States have access to influenza vaccines formulated for the southern hemisphere?Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection.Patterns of illness in travelers visiting Mexico and Central America: the GeoSentinel experience.The Onchocerca volvulus homologue of the multifunctional polypeptide protein disulfide isomerase.Globally mobile populations and the spread of emerging pathogens.Should testing of donors be restricted to active Zika virus areas?Effect of aggressive prolonged diethylcarbamazine therapy on circulating antigen levels in bancroftian filariasis.Japanese encephalitis: is there a need for a novel vaccine?Eggs of Schistosoma mansoni stimulate endothelial cell proliferation in vitro.Imported malaria--here to stay.Underestimate of annual malaria imports to Canada.The efficacy of ivermectin in the chemotherapy of gastrointestinal helminthiasis in humans.TAPI polymorphisms in several human ethnic groups: characteristics, evolution, and genotyping strategies.Response to "Selection bias".Re-born in the USA: Another cholera vaccine for travellersImminent Departures: Rapid Vaccination Strategies Designed to Induce Short-Term Immunogenicity for the Trip at HandDetection of Infectious Diseases Using Unofficial SourcesTravel medicine, a speciality on the moveTravelers as Sentinels for Disease Occurrence in Destination Countries
P50
Q21032503-DD2DC8D3-779F-4DCB-A136-2EACDD8F8AD1Q24247105-3191F554-ADB1-4F3E-A673-07367F918050Q26741256-60F02BF7-22D7-4B8B-8C69-C241A506FE5EQ30429276-CD3D248C-B99A-4645-B834-48563631B4D4Q33880771-16E235F2-7EC0-4260-B193-EFB06D7B6701Q34169263-A2DFC0C1-9EE9-4FFE-BE1F-815F2FB835E9Q34526753-1B762D4B-AAB3-428A-B4AF-7A1E72055882Q36239501-E3C65709-8008-4FDE-8633-8666DEBB2A8AQ36623443-651DD38C-61DB-4A57-91F0-BC6AC7C56714Q36641864-D0BA4382-63C9-4EB0-8245-EE0982657FF9Q36925471-A543F439-FE7E-4548-8DF5-DB9BF0B7A749Q37009420-657E62E3-187E-4757-98FB-6834D656875AQ37021081-ACBA8638-33C9-42D0-8CC4-C312BB8DF15FQ37230471-9333CFA7-FCEA-4023-9CAF-091980B37733Q37524448-080F3051-4997-4355-9FFA-C001876817C1Q37591112-F82432D8-6482-42A9-94FF-16858263CC5BQ37677467-D71B3336-A69B-4F10-AFCC-77225FCE3CA4Q39011352-5871D828-067C-40E4-B78E-9F889B5886DAQ39032840-C6919075-0375-45AD-8020-09C41CDD13E6Q39067681-C096D552-B844-4E5B-B74D-243ABC4A304EQ39436538-AD02B98F-C07F-4869-9E90-3D76276BC65CQ39493974-7C6E2CB0-447D-4630-BE52-7A59EAF3E92EQ39517791-AD028212-F011-4895-89D8-A53B53D022B5Q40315662-13AFD2D4-96AE-4357-A8B9-715585AABF3DQ42691842-67658CAF-E575-4FA0-85A4-E11C5646E097Q42831999-C5E060AA-B22B-4A10-AD21-07693461ED5EQ42997910-04299CAB-B9DF-4CEF-B65A-11E0DACFD2DCQ43544138-4E28454B-190E-4536-8B72-A9F01A8DBC41Q44429622-947D7F83-6F2C-4639-865F-FD6979E56131Q45922625-733262A9-A9F8-4495-BE91-ABACD641D13DQ47858541-701ACE52-8045-495D-87E6-3EE96E4C64ECQ47985382-044F9845-BA58-43D5-BCCA-7048FA22C845Q52454817-87FA307D-2765-4DAC-92F7-C9AF41976723Q52843882-C998C3E6-240E-4AA0-B6CE-D2F69FBB9134Q53724305-5904D2E8-CE5C-484F-A26A-4DB851705CA1Q56514978-D308FABB-2C37-4C32-8C14-9FA3E39A582CQ56515057-61A0A01C-7A29-4C87-B785-1698CEEBC971Q56515454-100BBEBB-1D5E-47EC-A626-5EEDD7D17F3DQ56515556-D9A37F1F-2A74-4711-AA6B-429ECAE5CD27Q56515569-D0050588-938D-4AC5-9B16-A1FC18461CE9
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
David O Freedman
@nl
David O Freedman
@sl
David O. Freedman
@en
David O. Freedman
@es
type
label
David O Freedman
@nl
David O Freedman
@sl
David O. Freedman
@en
David O. Freedman
@es
prefLabel
David O Freedman
@nl
David O Freedman
@sl
David O. Freedman
@en
David O. Freedman
@es
P214
P244
P106
P1153
7201528727
P21
P214
P244
P31
P496
0000-0002-5642-5257
P734
P735
P7859
lccn-n97800071